Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pliant Therapeutics Inc (NQ: PLRX ) 11.00 -0.20 (-1.79%) Streaming Delayed Price Updated: 10:01 AM EDT, Jun 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 24,872 Open 11.17 Bid (Size) 10.93 (4) Ask (Size) 11.03 (4) Prev. Close 11.20 Today's Range 10.99 - 11.23 52wk Range 10.60 - 22.52 Shares Outstanding 35,937,937 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors June 13, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 12, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Performance YTD -38.75% -38.75% 1 Month -27.25% -27.25% 3 Month -24.66% -24.66% 6 Month -33.21% -33.21% 1 Year -50.32% -50.32% More News Read More Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™ June 06, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings May 07, 2024 Via Benzinga The Latest Analyst Ratings for Pliant Therapeutics November 10, 2023 Via Benzinga Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference May 21, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients May 14, 2024 Via Benzinga Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis May 14, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™ May 07, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024 May 06, 2024 Via InvestorPlace Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results May 06, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in Upcoming Investor Events May 01, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in Upcoming Investor Events April 02, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference March 27, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis March 12, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results February 27, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in Upcoming Investor Conferences February 26, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in Upcoming Investor Events February 07, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 05, 2024 Via Benzinga Why Is Liver Disease-Focused Pliant Therapeutics Stock Trading Lower Today? February 05, 2024 Via Benzinga HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know February 05, 2024 Via Benzinga Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis February 04, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis November 13, 2023 From Pliant Therapeutics, Inc. Via GlobeNewswire Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results November 09, 2023 From Pliant Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
